Microbial HSPs (heat-shock proteins) are implicated in the induction of the innate and adaptive arms of the immune response. We set out to determine whether peptides complexed with HSP70 generate efficient CTL (cytolytic T-lymphocyte) responses. Human dendritic cells pulsed with peptide-loaded microbial HSP70 complexes generate potent antigen-specific CTL responses. Using fluorescence anisotropy, we have calculated the peptide-binding affinity of mycobacterial HSP70 (K D = 14 µM) and show that 120 pM HSP70-bound peptide is sufficient to generate a peptide-specific CTL response that is four orders of magnitude more efficient than the peptide alone. Through the generation of mycobacterial HSP70 truncations, we find that the minimal 136 amino acid, mycobacterial HSP70 peptide-binding domain is sufficient to generate CTL responses. The design of an HSP70 mutant, in which the peptide-binding site of HSP70 is filled with a bulky hydrophobic residue, leads to a large decrease in the peptide-binding affinity. This mutant HSP70 retains stimulatory capacity but is unable to generate CTL and has separated antigen delivery from immunostimulation of dendritic cells.
Introduction
Heat-shock proteins (HSPs) are abundant and ubiquitous proteins found in all organisms and in a variety of subcellular locations. There are an increasing number of functions attributed to HSPs including the folding and unfolding of proteins and polypeptides [1] . This latter property is of interest to immunologists since the induction of protective tumour immunity and the generation of tumour-specific CTL (cytolytic T-lymphocyte) in murine models have been ascribed to HSPs and their bound peptides [2] .
The presentation of 'exogenous' antigens on to MHC class I molecules, termed cross-presentation, is important for the induction of immunity in viruses that do not infect antigen presenting cells and in the generation of protective responses against tumours. A role for HSPs in cross-presentation has been proposed [3] .
HSP70 contains an N-terminal nucleotide-binding domain (44 kDa) with ATPase activity and a C-terminal substratebinding domain (27 kDa). Analysis of the structure of the peptide-binding domain of the Escherichia coli HSP70, DnaK [4] , reveals that HSP70 has a single peptide-binding site, with a hydrophobic channel flanked by an arch allowing access of the substrate. The peptide-binding cavity is composed of a β-sandwich, and α-helices comprise the hinge and lid regions, closing the substrate-binding cavity without interacting directly with the bound peptide. Binding of ATP to HSP70 Key words: cross-presentation, cytolytic T-lymphocyte, dendritic cells, heat-shock protein, HSP70. Abbreviations used: CTL, cytolytic T-lymphocyte; DC, dendritic cells; HSP, heat-shock protein. 1 These authors have contributed equally to this work. 2 To whom correspondence should be addressed (email pjl30@cam.ac.uk).
results in higher frequency transitions between 'open' and 'closed' conformations of the molecule, allowing access of peptide to the substrate-binding cavity and resulting in fast on-and off-rates. Peptide binding stimulates ATP hydrolysis and a more stable HSP70-peptide interaction. However, even in the absence of the ATPase domain, truncated HSP70 proteins are capable of binding peptides [4] .
Through their ability to bind and deliver antigenic peptides, HSPs confer specificity on immune responses and have additional immunostimulatory properties. Different HSPs can act as adjuvants in vivo [5] and stimulate innate immune cells in vitro [6] . A number of cellular receptors for HSPs have been described, including CD91, CD14, CD40, TLR4 (Toll-like receptor 4) and Lox-1 [7] [8] [9] [10] [11] . It is not clear which receptors are responsible for uptake and/or proinflammatory signalling.
To optimize HSPs for therapeutic use, it is essential that the mechanism of peptide binding, peptide-binding affinity and the minimal HSP unit required to bind a peptide and generate CTL is elucidated. Since the structural basis of peptide binding is best understood for HSP70, we investigated the ability of mycobacterial HSP70-pulsed human DC (dendritic cells) to generate peptide-specific CTL [12] .
Results and discussion
To examine the efficiency of the generation of peptide-specific CTL responses, we modified a procedure of Bhardwaj et al. [13] ( Figure 1A ). This assay measures the ability of antigen-pulsed DC to generate an effector CTL population from freshly isolated CD8+ T-lymphocytes and represents a stringent test of antigen presentation. To ensure that the assay only measured the effects of peptide complexed with HSP70, free peptide was removed by overnight microdialysis.
To increase the affinity of the antigenic peptides for HSP70, we designed fusion peptides (17-23mers) that contained an N-terminal HSP70-binding motif (HWDFAWPW [14] or NRLLLTG [4] ) connected via a linker to influenza A-derived HLA-A*0201 (GILGFVFTL) or HLA-B8/27 (ELRSRYWAIRTR)-restricted CTL epitopes. Using mycobacterial HSP70-bound peptides, cells from 12/12 HLA-A*0201 healthy donors generated M1-specific CTL with specific lysis ranging from 19 to 55% at an E/T (effector to target) ratio of 10:1. The maximal response was seen with mycobacterial HSP70 complexed with the extended peptide NRL-M1, which by tetramer staining showed 35% of cells to be HLA-A*0201/M1 positive (Figure 1Bi ). Isolated CD8 + T-cells without DC were unable to elicit a response (Figure 1Bii ). In the absence of HSP70, free peptide was also unable to stimulate a response (Figure 1Biii ). In addition, the efficient generation of antigen-specific CTL by HSP70-peptide complexes was not simply due to activation of DC, since free peptide plus LPS (lipopolysaccharide), a potent DC activator, only generated a minimal specific CTL response (Figure 1Biv ). To determine the amount of peptide being delivered by the mycobacterial HSP70-peptide complexes to DC, we used fluorescence anisotropy to determine the equilibriumbinding affinity of peptide for HSP70. The N-terminally fluorescein-labelled NRL-M1 (fNRL-M1) peptide was highly insoluble, resulting in poorly reproducible data. Therefore we synthesized a fluorescent peptide (fN-RLLLTG) utilizing the HSP70-binding motif that bound mycobacterial HSP70 with similar affinity to fNRL-M1 (12 µM compared with 14 µM for fNRL-M1). We used these K D values to calculate that 120 pM HSP70-bound peptide is sufficient to generate peptide-specific CTL ( Figure 1C) , whereas a 2000-fold higher concentration of free peptide (250 nM) was unable to generate a similar response.
To determine the minimal functional HSP70 domain capable of inducing peptide-specific CTL, we made recombinant HSP70 truncation proteins. The HSP70 truncation, denoted HSP70 (359-610), contains the complete substratebinding domain, but lacks the nucleotide-binding domain and stimulates chemokine and cytokine release [6] . The smallest HSP70, denoted HSP70 (359-494) encompasses the minimal peptide-binding domain without the hinge and lid regions. The peptide-binding affinities for fNRLLLTG were measured by fluorescence anisotropy and were 12 µM for HSP70 (359-610) and 19 µM for HSP70 (359-494). Functional comparison with native mycobacterial HSP70 showed HSP70 (359-610) to be equally effective as wildtype HSP70 in generating antigen-specific CTL. The minimal HSP70 (359-494) was also efficient at generating CTL, with a small reduction in activity accountable by its 1.5-fold reduced affinity for peptide ( Figure 1D ). To ascertain whether the two functions of HSP70, peptide delivery and DC stimulation, were separable, we made HSP70 peptide-binding mutants. Mutation of a highly conserved valine residue to a bulky phenylalanine in the hydrophobic peptide-binding pocket of DnaK substantially reduces the affinity of HSP70 for peptide [15] . Therefore we mutated the corresponding valine residue (Val-410) in mycobacterial HSP70 to leucine (V410L) and phenylalanine (V410F) (Figure 2A) . A comparison of the affinity of these mutant proteins for peptide showed a 2-fold (V410L, K D = 27 µM) and at least 5.5-fold (V410F, K D = 65 µM) reduction in affinity compared with wild-type HSP70 (K D = 12 µM). The functional consequence of these mutations was tested in our CTL generation assay. DC pulsed with the HSP70 (V410F) mutant were unable to generate peptide-specific CTL, whereas CTL generation was significantly impaired with the conservative HSP70 (V410L) mutant ( Figure 2B ). However, both mutant HSP70s were equally effective as wild-type HSP70 in eliciting chemokine and cytokine release from DC. This HSP70 (V410F) mutant allowed us to speculate whether in the presence of excess, free peptide, the immunostimulatory properties of HSP70 are sufficient to generate CTL or whether there is an absolute requirement for peptide to be HSP bound. We compared CTL generation between DC pulsed with peptide alone, peptide-loaded, dialysed wild-type HSP70 (359-610) or peptide-loaded, non-dialysed HSP70 (V410F) ( Figure 2C ). Even when pulsed with 2000 nM free peptide, in the presence of HSP70 (V410F), poor generation of CTL was seen, which was comparable with the level of killing seen with dialysed wild-type HSP70 (359-610) with bound peptide at 0.21 nM (10 000 times less peptide). Thus, even in the presence of excess free peptide, the adjuvant properties of mycobacterial HSP70 are insufficient to generate the efficient generation of CTL compared with HSP70-bound peptide.
We have examined the role of mycobacterial HSP70 in generating human CTL responses. Human DC pulsed with mycobacterial HSP70-peptide complexes efficiently generate antigen-specific CTL. Truncated HSP70 containing the minimal 136-amino-acid peptide-binding domain is sufficient to elicit a CTL response. We show that HSP70 mutants, with a reduced affinity for peptide are unable to generate peptide-specific CTL despite inducing normal cytokine and chemokine release from DC. Thus we have separated the innate immunostimulatory properties of HSP70 from its ability to elicit antigen-specific CTL responses. The remarkable efficiency with which HSP70-peptide complexes generate CTL and the low concentrations of peptide required suggest a physiological role for HSP70-bound peptide in accessing the class I presentation pathway.
